Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 132Carcinoma, Transitional Cell 91Carcinoma, Non-Small-Cell Lung 84Urinary Bladder Neoplasms 81Melanoma 75Squamous Cell Carcinoma of Head and Neck 50Prostatic Neoplasms 49Colorectal Neoplasms 41Ovarian Neoplasms 36Stomach Neoplasms 35Triple Negative Breast Neoplasms 33Neoplasm Metastasis 32Uterine Cervical Neoplasms 31Neoplasms 28Kidney Neoplasms 27Breast Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 26Lung Neoplasms 26Pancreatic Neoplasms 23Carcinoma, Hepatocellular 23Esophageal Neoplasms 21Head and Neck Neoplasms 20Endometrial Neoplasms 18Small Cell Lung Carcinoma 16Carcinoma, Merkel Cell 11Mesothelioma 9Cholangiocarcinoma 9Ureteral Neoplasms 8Sarcoma 8Carcinoma, Ovarian Epithelial 8

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × pembrolizumab × Genitourinary × Clear all
NCT03547973 2026-03-16

TROPHY U-01

Gilead Sciences

Phase 2 Recruiting
827 enrolled 1 FDA
Genitourinary

Metastatic Urothelial Cancer

NCT02826564 2024-07-17

Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer

University Hospital, Ghent

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡